All News

The FDA’s approval of the Opdivo plus platinum-doublet chemotherapy regimen marks the agency’s first greenlight, according to manufacturer Bristol Myers Squibb, of an immunotherapy-based treatment in the pre-surgical setting for non-small cell lung cancer.

The metastatic breast cancer community is a unique, strong-willed group of people who were honored in our inaugural Metastatic Breast Cancer HeroesTM program.

From the use of anti-depressants to cryotherapy, researchers continue to explore potential ways to mitigate the side effects that are associated with breast cancer therapy.

The study authors plan to enroll 32 patients with advanced pancreatic cancer into the trial to assess the efficacy and safety of an experimental treatment combination.

As humans, we have an inherent need to know why everything happens in our life — including a cancer diagnosis. But unfortunately, that is not always the case.

From a “Jeopardy!” winner taking her wig off on the gameshow to childhood patients with cancer in Ukraine being bussed to neighboring countries to safely receive treatment, here’s what’s happening in the cancer space this week.

During his college years, Matt Froestad received the diagnosis not once but twice following self-exams.

The most revealing thing that Dr. Bhuvaneswari Ramaswamy, a breast medical oncologist, learned during her own treatment for breast cancer was that despite having extraordinary family and medical support, she still felt very isolated.

Significant challenges include improving detection and response to inner ear side effects among cancer survivors following the use of certain drugs and therapies.

If an oncologist was apprehensive about Steven Edwards getting a second opinion, that might not be the right doctor for him, the kidney cancer survivor said.

As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about improving patient-physician communication throughout myeloma care.

As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about treating myeloma as a chronic disease and how the multidisciplinary approach to care can assist in challenges, like financial toxicity.

CAR-T cell therapies offer patients with lymphoma a chance for long-term remission, but none have yet to receive a greenlight from the FDA as a first line of treatment.

The number of people developing leptomeningeal disease is increasing for the same reason that diagnoses of brain metastases are on the rise: People are living longer, giving cancer more time to spread.

I’ve recently joined the masses in catching up with routine health care that was put off during the COVID-19 pandemic.

Guidelines for the treatment of patients with brain metastases is moving from whole brain radiation therapy to less toxic treatment options to potentially improve care and increase survival.

As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about raising awareness for multiple myeloma, and why sharing one’s story is helpful for others.

Treatment with ofatumumab plus an aggressive regimen of chemotherapies resulted in a response rate of more than 80% in patients with newly diagnosed mantle cell lymphoma.

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma.

Better therapies are on the horizon for cancer that has spread to the brain, including a clinical trial that matches patients with treatments based on unique genetic changes in brain metastases.

In spending just a few minutes a day on Twitter, I’ve created a support group with other cancer survivors who know how it feels to face the disease.

The Food and Drug Administration’s greenlight of Vonjo marks the first approved therapy to address the needs of patients with cytopenic myelofibrosis, a type of myeloproliferative neoplasm.

Ninety-eight percent of patients with pretreated relapsed/refractory myeloma responded to treatment with Carvykti, a newly approved CAR-T cell therapy for this patient population.

When caregivers — considered by many to be an essential part of a patient’s care team — have the tools they need to care for themselves and their loved ones, cancer outcomes can be better, too.

When I was diagnosed with cancer, I thought of only two things: my loved ones and how much time I had left with them.

The post-scanxiety crash felt like an avalanche for me, and even though my scans were clear, it took talking to another cancer survivor to snap me out of it.

The Food and Drug Administration plans to speed up its review of Opdivo in the pre-surgical setting for patients with non-small cell lung cancer.

There are now more drugs than ever to treat and prevent graft-versus-host disease in patients with blood cancer who receive a stem cell transplant.